Effective Doses and Predictors of Dexmedetomidine for Inducing Specific Sleep Stages (N2/N3) in Chronic Insomnia: A Retrospective Cohort Study
Zhenxiu Liu, Zhouquan Wu, Renqun Wang, Dandan Yin, Huichan Xv, Panqi Wang, Fuhai Ji, Jingjing Shen · 2026
Read Effective Doses and Predictors of Dexmedetomidine for Inducing Specific Sleep Stages (N2/N3) in Chronic Insomnia: A Retrospective Cohort Study by Zhenxiu Liu, Zhouquan Wu, Renqun Wang, Dandan Yin, Huichan Xv, Panqi Wang, Fuhai Ji, Jingjing Shen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13157349.txt.
Description
Zhenxiu Liu and seven co-authors report a 2026 study of dexmedetomidine, a drug that can induce sleep-like states, in chronic insomnia. The team asked what dose brings on two sleep stages, N2 and N3, read from brain wave scans. They also asked which patient traits shift the dose.
The study held 252 adults who got the drug by vein with steady brain checks. The median dose was 40 micrograms for N2 sleep and 55 for the deeper N3 stage. Higher body mass index meant a higher dose for both stages. Worse depression scores raised the dose for N2 only, and age had no clear effect. The authors back dose plans tuned to each patient with brain wave guidance.
Catalog record
| CREATOR | Zhenxiu Liu, Zhouquan Wu, Renqun Wang, Dandan Yin, Huichan Xv, Panqi Wang, Fuhai Ji, Jingjing Shen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |